CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.18524936

Available online at: http://www.iajps.com Review Article

THE EXPANDING THERAPEUTIC LANDSCAPE OF GLP-1 RECEPTOR AGONISTS BEYOND DIABETES

Gayatri S. Bansode[1]. Rupal R.Walke[2,]
JSPM'S Rajarshi Shahu College Of Pharmacy and Research Tathwade, Pune [1,2]

Abstract:
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were initially introduced as incretin-based agents for the treatment of type 2 diabetes mellitus (T2DM). Over recent years, extensive experimental, clinical, and population-based studies have revealed that these agents exert wide-ranging biological effects extending far beyond glucose regulation. GLP-1RAs influence appetite control, body weight, cardiovascular outcomes, renal function, hepatic lipid metabolism, and neuroinflammatory pathways. Advances in incretin pharmacology, including dual and multi-agonist molecules, have further broadened their therapeutic scope. This review critically examines the molecular mechanisms and clinical evidence supporting the extra-glycemic benefits of GLP-1 receptor agonists, highlighting their emerging role as multisystem disease-modifying therapies.
Keywords: *GLP-1 receptor agonists; incretin signaling; cardiometabolic disease; chronic kidney disease; obesity; NAFLD; neuroprotection*

Corresponding author:
Gayatri S. Bansode,
JSPM'S Rajarshi Shahu College Of Pharmacy and Research Tathwade, Pune

QR CODE

Please cite this article in** press Gayatri S. Bansode **et al., The Expanding Therapeutic Landscape Of Glp-1 Receptor Agonists Beyond Diabetes, Indo Am. J. P. Sci, 2026; 13(01).



1. INTRODUCTION:

Type 2 diabetes mellitus is no longer viewed solely as a disorder of impaired glucose homeostasis but rather as a complex systemic disease associated with obesity, cardiovascular disease, chronic kidney disease (CKD), non-alcoholic fatty liver disease (NAFLD), and neurodegenerative conditions. Conventional glucose-lowering therapies often demonstrate limited efficacy in preventing these long-term complications.

GLP-1 receptor agonists have transformed the therapeutic landscape of metabolic disease. Although initially developed to improve glycemic control, accumulating evidence demonstrates that these agents exert beneficial effects across multiple organ systems, largely due to the widespread distribution of GLP-1 receptors and activation of diverse intracellular signaling pathways [1–3].

2. Physiology of GLP-1 and Intracellular Signaling

Glucagon-like peptide-1 is an incretin hormone synthesized from proglucagon and released by intestinal L-cells following nutrient intake. It enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and promotes satiety [21].

The GLP-1 receptor is a G-protein–coupled receptor expressed in pancreatic β-cells, the central nervous system, cardiovascular tissues, kidneys, liver, and gastrointestinal tract [15,24]. Upon activation, the receptor stimulates cyclic AMP-dependent signaling cascades involving protein kinase A (PKA) and Epac, which regulate insulin biosynthesis, mitochondrial integrity, inflammatory responses, and cellular survival [3,38]. These molecular mechanisms underlie the pleiotropic actions of GLP-1 receptor agonists.

3. Cardiovascular Benefits Independent of Glycemic Control

Cardiovascular disease remains the primary cause of mortality in individuals with diabetes and obesity. Evidence from randomized clinical trials, meta-analyses, and large real-world datasets consistently demonstrates that GLP-1 receptor agonists reduce the incidence of major adverse cardiovascular events, including myocardial infarction and stroke, as well as cardiovascular mortality [1,10,40,41].

At the molecular level, GLP-1RAs improve endothelial nitric oxide bioavailability, reduce systemic inflammation, lower blood pressure, and inhibit atherosclerotic plaque progression. Importantly, these cardioprotective effects are only partially attributable to glucose lowering or weight reduction, suggesting direct cardiovascular actions [2,11].

4. Renal Protective Effects in Chronic Kidney Disease

Chronic kidney disease is a frequent complication of metabolic disorders and a strong predictor of adverse cardiovascular outcomes. Growing evidence indicates that GLP-1 receptor agonists slow CKD progression by reducing albuminuria and preserving renal function, even in patients with advanced diabetic kidney disease [4,18,30].

These renoprotective effects appear to result from anti-inflammatory actions, improved renal hemodynamics, natriuresis, and modulation of tubuloglomerular feedback rather than glycemic control alone [30,43]. Consequently, clinical guidelines now endorse GLP-1RAs for patients with T2DM and CKD who remain at high cardiometabolic risk [5].

5. Hepatic Effects in Metabolic Liver Disease

NAFLD and non-alcoholic steatohepatitis represent major metabolic complications associated with insulin resistance and obesity. Clinical studies and meta-analyses demonstrate that GLP-1 receptor agonists reduce hepatic fat content, improve liver enzyme levels, and promote histological improvement in steatohepatitis [6,19].

The hepatoprotective effects of GLP-1RAs are mediated through sustained weight loss, enhanced insulin sensitivity, suppression of hepatic lipogenesis, and stimulation of fatty acid oxidation, supporting their therapeutic potential in metabolic liver disease [19].

6. Anti-Obesity Effects and Regulation of Energy Balance

GLP-1 receptor agonists produce robust and sustained reductions in body weight by acting on central appetite-regulating circuits and delaying gastric emptying. Clinical trials confirm significant reductions in body weight, body mass index, and visceral adiposity in both diabetic and nondiabetic individuals [7,12,27].

Recent advances in incretin pharmacology have led to the development of dual GLP-1/GIP receptor agonists, which demonstrate superior weight-loss efficacy and metabolic benefits compared with GLP-1 monotherapy, emphasizing the importance of hormonal synergy in energy homeostasis [17,29].

7. Neuroprotective and Neurodegenerative Implications

GLP-1 receptors are widely distributed throughout the brain, including regions involved in cognition, motor coordination, and reward processing. Emerging evidence suggests that GLP-1 receptor agonists attenuate neuroinflammation, reduce oxidative stress, and protect against neuronal apoptosis, indicating potential disease-modifying effects in neurodegenerative disorders [31–35].

Preclinical and early clinical studies demonstrate that agents such as semaglutide and liraglutide preserve dopaminergic neuron integrity, enhance autophagic pathways, and improve neurovascular function, highlighting their promise in Alzheimer's and Parkinson's diseases [34,35].

8. Emerging Extra-Metabolic Effects

Beyond traditional metabolic indications, GLP-1 receptor agonists exhibit anti-inflammatory, cytoprotective, and immunomodulatory properties. Recent studies suggest potential therapeutic roles in substance-use disorders, pulmonary disease, neurovascular dysfunction, and heart failure with preserved ejection fraction, particularly in obesity-related phenotypes [11,35,44].

9. Safety Profile and Clinical Considerations

GLP-1 receptor agonists are generally well tolerated, with gastrointestinal symptoms such as nausea and vomiting being the most commonly reported adverse effects. Although rare risks of pancreatitis, gallbladder disease, and thyroid-related events have been reported, the overall benefit–risk profile remains favorable when patients are appropriately selected and monitored [7,10,11,36].

10. Future Directions

Future research should prioritize elucidation of tissue-specific molecular mechanisms, identification of biomarkers predictive of therapeutic response, and optimization of combination therapies. Dual and multi-incretin agonists represent a promising next generation of incretin-based treatments with applications extending well beyond diabetes [29,44].

11. CONCLUSIONS:

GLP-1 receptor agonists have evolved from glucose-lowering medications into multifunctional therapeutic agents with significant effects on cardiovascular health, renal function, hepatic metabolism, body composition, and brain integrity. Their broad molecular actions and expanding clinical evidence establish GLP-1RAs as cornerstone therapies in modern precision medicine beyond diabetes management.

REFERENCES:

1. Krishnan A, et al. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in NAFLD and T2DM. *Diabetologia*. 2024.

2. Westermeier F, Fisman EZ. GLP-1 receptor agonists and cardiometabolic protection. *Cardiovasc Diabetol*. 2025.
3. Rowlands J, et al. Pleiotropic effects of GLP-1 on cell signaling and metabolism. *Front Endocrinol*. 2018.
4. Siniukovich A, et al. Impact of GLP-1 receptor agonists on cardiovascular and renal outcomes in CKD. *Diabetol Metab Syndr*. 2025.
5. ADA–KDIGO Consensus Report. Diabetes management in chronic kidney disease. *Diabetes Care*. 2022.
6. Ghosal S, et al. GLP-1 receptor agonists in NAFLD with T2DM: A meta-analysis. *Sci Rep*. 2021.
7. Irfan H, et al. Role of GLP-1 receptor agonists in weight loss in T2DM. *Cureus*. 2023.
8. Vahora I, et al. GLP-1 receptor agonists for weight loss in non-diabetic patients. *Cureus*. 2024.
9. Katole NT, et al. Anti-obesity effects of GLP-1 receptor agonists in adolescents. *Cureus*. 2024.
10. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. *Drugs in Context*. 2015.
11. Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. *Nature Medicine*. 2025.
12. Son JW, Lim S. GLP-1-based therapies in obesity management. *Endocrinol Metab*. 2024
13. Knudsen LB, Lau J. Discovery and development of liraglutide and semaglutide. *Front Endocrinol*. 2019.
14. Cai W, et al. Tirzepatide as a novel strategy for obesity. *Front Public Health*. 2024.
15. Cooper ME, van Raalte DH. GLP-1 agonists in chronic kidney disease. *J Clin Invest*. 2025.
16. Mahapatra MK, et al. Therapeutic potential of semaglutide beyond diabetes. *Pharm Res*. 2022.
17. Koye DN, et al. Global epidemiology of diabetes and kidney disease. *Adv Chronic Kidney Dis*. 2018.
18. Hoang V, et al. Liraglutide improves hypertension in PCOS model. *PLoS ONE*. 2015.
19. Bruns VI N, et al. GLP-1 and substance use disorders. *Pharmacol Res*. 2024. GB NAFDAL
20. Xu D, et al. Potential roles of GLP-1 receptor agonists in nondiabetic populations. *Cardiovasc Ther*. 2022.
21. Nauck MA, et al. Preserved incretin activity of GLP-1 in type 2 diabetes. *J Clin Invest*. 1993.
22. Nauck MA, et al. GLP-1 vs GIP insulinotropic effects in T2DM. *J Clin Invest*. 1993.
23. Tan Q, et al. Recent advances in incretin-based pharmacotherapies. *Front Endocrinol*. 2022.
24. Flint A, et al. GLP-1 promotes satiety and suppresses energy intake. *J Clin Invest*. 1998.
25. Tan Q, et al. GLP-1 signaling and obesity pharmacotherapy. *Front Endocrinol*. 2022.
26. Duan K, et al. Effect of GLP-1 receptor agonists on fat distribution. *J Diabetes Investig*. 2022.
27. Christensen M, et al. GIP as a bifunctional regulator of insulin and glucagon. *Diabetes*. 2011.
28. Tan Q, et al. Dual incretin agonism and metabolic control. *Front Endocrinol*. 2022.
29. Cooper ME, van Raalte DH. GLP-1 agonists in chronic kidney disease. *J Clin Invest*. 2025.
30. Kopp KO, et al. GLP-1 receptor agonists and neuroinflammation. *Pharmacol Res*. 2022.
31. Kalinderi K, et al. GLP-1 receptor agonists in Parkinson's disease. *Int J Mol Sci*. 2024.
32. Monti G, et al. GLP-1 receptor agonists in neurodegeneration. *Cells*. 2022.
33. Zhang L, et al. Neuroprotective effects of semaglutide in Parkinson's disease models. *Neuropeptides*.
34. Monti G, et al. GLP-1 and neurovascular unit integrity. *Cells*. 2022.
35. Glotfelty EJ, et al. GLP-1-based receptor agonists as a treatment for Parkinson's disease. *Expert Opin Investig Drugs*. 2020.
36. Kupnicka P, et al. GLP-1 receptor agonists: a promising therapy for modern lifestyle diseases. *Pharmaceuticals*. 2024.
37. Doyle ME, Egan JM. Mechanisms of action of GLP-1 in the pancreas. *Pharmacol Ther*. 2007.
38. Zheng Z, et al. GLP-1 receptor: mechanisms and advances in therapy. *Signal Transduct Target Ther*. 2024.
39. Duan K, et al. Effect of GLP-1 receptor agonists on fat distribution. *J Diabetes Investig*. 2022.
40. Lin Y, et al. Cardiovascular and renal effects of GLP-1 receptor agonists in advanced diabetic kidney disease. *Cardiovasc Diabetol*. 2023.
41. Chen X, et al. Effects of GLP-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes. *Diabetol Metab Syndr*. 2024.
42. Lin Y, et al. GLP-1RA versus DPP-4 inhibitors in diabetic kidney disease. *Cardiovasc Diabetol*. 2023.
43. Lin Y, et al. Renal outcomes of GLP-1 receptor agonists in advanced CKD. *Cardiovasc Diabetol*. 2023.
44. Zile MR, et al. Effects of tirzepatide in heart failure with preserved ejection fraction and obesity. *Circulation*. 2025.
45. Monti G, et al. GLP-1 receptor agonists in neurodegeneration. *Cells*. 2022.